The demand for real world evidence (RWE) has skyrocketed among key stakeholders across the entire healthcare value chain: physicians, thought leaders, providers, payers, regulatory bodies, and other groups.
In response, pharmaceutical and medical device companies are taking rapid steps to increase the precision and speed of their RWE capabilities. This critical trend is evident in the actions taken by Medical Affairs functions across the industry, which are quickly adopting more formal RWE processes, pursuing innovation, building the total data package, and utilizing RWE earlier in the product lifecycle.
This research examine how Medical Affairs teams from leading pharmaceutical and medical device companies are using real world evidence to achieve maximum impact along patient, disease state, clinical, payer and other value fronts.
This report evaluates the role of Medical Affairs in RWE strategic decision making, oversight, evidence gap assessment, and interpretation of medical and clinical value of health outcomes. The report also delivers benchmarks around real world data sources, collection, evaluation, utilization, evidence generation, investment, and overall key performance indicators.